High Blood Pressure and Common Medications
High blood pressure, often referred to as hypertension, is a global health issue affecting over a billion individuals worldwide. Many of those diagnosed are typically prescribed medications such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). These drugs are designed to interact with the renin-angiotensin system (RAS) to help manage blood pressure levels. Despite this, many patients continue to struggle with uncontrolled hypertension, indicating a pressing need for alternative treatments.
Insights from Penn Dental Medicine's Recent Study
In an enlightening study published in Hypertension Research, researchers from Penn Dental Medicine embarked on an investigation to examine how adding oral ACE2 could enhance the effectiveness of current hypertension therapies. ACE2 has previously demonstrated beneficial effects when delivered through injections, particularly in metabolic disorders linked to the renin-angiotensin system.
The Role of ACE2
According to Henry Daniell, a key figure in the research and the W.D. Miller Professor at Penn Dental Medicine, ACE2 plays a crucial role in regulating hypertension and heart disease. Surprisingly, the relationship between common blood pressure medications and ACE2 hadn’t been thoroughly studied until now.
How RAS Impacts Blood Pressure
The renin-angiotensin system is vital in regulating blood pressure. When blood pressure drops, the body releases renin, which transforms angiotensinogen into angiotensin I. The angiotensin-converting enzyme (ACE) then converts this to angiotensin II—a potent vasoconstrictor. ACEIs curb the production of angiotensin II, while ARBs prevent it from binding to its receptors. ACE2 has a counteractive role, reducing angiotensin II levels and promoting vasodilation, which aids in lowering blood pressure.
Benefits and Surprises from the Research
In their research, Daniell and his team built upon prior work that evaluated the oral delivery of ACE2 using a plant-based encapsulation system, specifically in cases involving dogs suffering from myxomatous mitral valve disease. These canine subjects often struggled with elevated systolic blood pressure and were treated with ACEIs and ARBs.
The results of their study revealed some unexpected challenges. Daniell noted that the first surprising finding was that ACE inhibitors, which were meant to enhance treatment, actually inhibited the activity of ACE2. A second finding indicated that ARBs inadvertently increased angiotensin II levels, impacting blood pressure regulation negatively.
Next Steps in Research
Moving forward, the researchers plan to repeat the experiments using lisinopril, an ACE inhibitor that did not inhibit ACE2 activity significantly in their initial findings. Daniell hopes that through further research, they can effectively assess the advantages of ACE2 treatments in human patients.
Potential Implications for Treatment
The findings from this study could lead to a reevaluation of how certain medications are used in treating high blood pressure. If ACE2 can be successfully integrated into treatment protocols, it may offer a new avenue for managing hypertension effectively. The adaptability of treatments based on new research is a promising step forward in cardiology.
Frequently Asked Questions
What is high blood pressure?
High blood pressure, or hypertension, is a health condition where the force of the blood against the artery walls is consistently too high, which can lead to serious health issues.
What are ACEIs and ARBs?
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two types of medications commonly prescribed to help regulate blood pressure.
What was the aim of the Penn Dental Medicine study?
The study aimed to evaluate the effects of adding oral ACE2 to existing treatments for hypertension, as it has potential benefits for regulating blood pressure.
What were the main findings of the study?
The researchers discovered that ACEIs inhibited ACE2 activity and that ARBs increased angiotensin II levels, both of which could undermine hypertension treatment efforts.
What is the next phase of research?
The next step is to replicate the study with lisinopril to better understand its effects on ACE2 and blood pressure management.
